NuVasive to buy back up to $230 million of 2.25% convertibles due 2013

By Toni Weeks

San Diego, June 21 - NuVasive, Inc. intends to use the proceeds of its planned offering of $325 million convertible senior notes due 2017 to repurchase up to $230 million of its 2.25% convertible senior notes due March 2013 and for general corporate purposes, according to a press release.

The company said it may consider possible acquisitions of or investments in companies, technologies, products or assets.

In addition, NuVasive may use a portion of the proceeds to pay for the cost of convertible note hedge transactions that it intends to enter into with one or more of the underwriters or their affiliates. The purpose of the hedge transactions is to reduce the company's exposure to potential cash payments and/or the dilution experienced by NuVasive's stockholders upon any conversion of the notes.

NuVasive, based in San Diego, is a medical device company focused on developing minimally disruptive products and procedures for the spine.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.